candesartan has been researched along with Pregnancy in 20 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 9.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "Schizophrenia is a severe mental disorder with complex etiopathogenesis." | 5.62 | Low-dose candesartan prevents schizophrenia-like behavioral alterations in a neurodevelopmental two-hit model of schizophrenia. ( da Silva, FER; de Lucena, DF; Dos Santos Júnior, MA; Lima, CNC; Macedo, DS; Medeiros, IDS; Monte, AS; Moreira Lima Neto, AB; Teixeira, AL; Vasconcelos, GS; Vasconcelos, SMM, 2021) |
| "Gestational hypertension was markedly improved by treatment of Candesartan compared with the control." | 5.48 | Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway. ( Wang, X; Zhao, X, 2018) |
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 5.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "Betamethasone is administered to accelerate lung development and improve survival of premature infants but may be associated with hypertension later in life." | 3.78 | Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure. ( Chappell, MC; Diz, DI; Rose, JC; Shaltout, HA, 2012) |
| "Schizophrenia is a severe mental disorder with complex etiopathogenesis." | 1.62 | Low-dose candesartan prevents schizophrenia-like behavioral alterations in a neurodevelopmental two-hit model of schizophrenia. ( da Silva, FER; de Lucena, DF; Dos Santos Júnior, MA; Lima, CNC; Macedo, DS; Medeiros, IDS; Monte, AS; Moreira Lima Neto, AB; Teixeira, AL; Vasconcelos, GS; Vasconcelos, SMM, 2021) |
| "Gestational hypertension was markedly improved by treatment of Candesartan compared with the control." | 1.48 | Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway. ( Wang, X; Zhao, X, 2018) |
| "A pregnant young woman with a severe migraine is prescribed candesartan, an angiotensin II type 1 receptor antagonist (AT II antagonists)." | 1.36 | Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. ( Haaland, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neuper, L | 1 |
| Kummer, D | 1 |
| Forstner, D | 2 |
| Guettler, J | 1 |
| Ghaffari-Tabrizi-Wizsy, N | 1 |
| Fischer, C | 2 |
| Juch, H | 1 |
| Nonn, O | 2 |
| Gauster, M | 2 |
| Geisberger, S | 1 |
| El-Heliebi, A | 1 |
| Kroneis, T | 1 |
| Desoye, G | 1 |
| Staff, AC | 1 |
| Sugulle, M | 1 |
| Dechend, R | 1 |
| Pecks, U | 1 |
| Kollmann, M | 1 |
| Stern, C | 1 |
| Cartwright, JE | 1 |
| Whitley, GS | 1 |
| Thilaganathan, B | 1 |
| Wadsack, C | 1 |
| Huppertz, B | 1 |
| Herse, F | 1 |
| Vasconcelos, GS | 1 |
| Dos Santos Júnior, MA | 1 |
| Monte, AS | 1 |
| da Silva, FER | 1 |
| Lima, CNC | 1 |
| Moreira Lima Neto, AB | 1 |
| Medeiros, IDS | 1 |
| Teixeira, AL | 1 |
| de Lucena, DF | 1 |
| Vasconcelos, SMM | 1 |
| Macedo, DS | 1 |
| Zhao, X | 1 |
| Wang, X | 1 |
| Ishii, M | 1 |
| Hattori, A | 1 |
| Numaguchi, Y | 1 |
| Ma, X | 1 |
| Nagasaka, T | 1 |
| Tsujimoto, M | 1 |
| Murohara, T | 1 |
| Kobayashi, H | 1 |
| Mizutani, S | 1 |
| Borthen, C | 1 |
| Oglaend, B | 1 |
| Eggebøe, T | 1 |
| Ellingsen, CL | 1 |
| Schjøtt, J | 1 |
| Haaland, K | 1 |
| Contag, SA | 1 |
| Bi, J | 1 |
| Chappell, MC | 3 |
| Rose, JC | 3 |
| Munk, PS | 1 |
| von Brandis, P | 1 |
| Larsen, AI | 1 |
| Shaltout, HA | 2 |
| Figueroa, JP | 1 |
| Diz, DI | 2 |
| Averill, DB | 1 |
| Porta, M | 1 |
| Hainer, JW | 1 |
| Jansson, SO | 1 |
| Malm, A | 1 |
| Bilous, R | 1 |
| Chaturvedi, N | 1 |
| Fuller, JH | 1 |
| Klein, R | 1 |
| Orchard, T | 1 |
| Parving, HH | 1 |
| Sjølie, AK | 1 |
| Hünseler, C | 1 |
| Paneitz, A | 1 |
| Friedrich, D | 1 |
| Lindner, U | 1 |
| Oberthuer, A | 1 |
| Körber, F | 1 |
| Schmitt, K | 1 |
| Welzing, L | 1 |
| Müller, A | 1 |
| Herkenrath, P | 1 |
| Hoppe, B | 1 |
| Gortner, L | 1 |
| Roth, B | 1 |
| Kattner, E | 1 |
| Schaible, T | 1 |
| Schlaich, MP | 1 |
| Cox, RM | 1 |
| Anderson, JM | 1 |
| Cox, P | 1 |
| Cairns, MJ | 1 |
| Burns, P | 1 |
| Di Nicolantonio, R | 1 |
| McKinley, MJ | 1 |
| Mathai, ML | 1 |
| Bald, M | 1 |
| Holder, M | 1 |
| Zieger, M | 1 |
| Vochem, M | 1 |
| Leichter, HE | 1 |
| Simonetti, GD | 1 |
| Baumann, T | 1 |
| Pachlopnik, JM | 1 |
| von Vigier, RO | 1 |
| Bianchetti, MG | 1 |
| Payen, V | 1 |
| Chemin, A | 1 |
| Jonville-Béra, AP | 1 |
| Saliba, E | 1 |
| Cantagrel, S | 1 |
| Hinsberger, A | 1 |
| Wingen, AM | 1 |
| Hoyer, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)[NCT03310684] | 160 participants (Anticipated) | Observational | 2018-12-03 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
1 review available for candesartan and Pregnancy
| Article | Year |
|---|---|
[Fetal toxicity of angiotensin-II receptor antagonists].
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Fe | 2006 |
1 trial available for candesartan and Pregnancy
18 other studies available for candesartan and Pregnancy
| Article | Year |
|---|---|
Candesartan Does Not Activate PPARγ and Its Target Genes in Early Gestation Trophoblasts.
Topics: Angiotensin II; Female; Humans; Placenta; Placentation; PPAR gamma; Pregnancy; Receptor, Angiotensin | 2022 |
Maternal Angiotensin Increases Placental Leptin in Early Gestation via an Alternative Renin-Angiotensin System Pathway: Suggesting a Link to Preeclampsia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Benzimidazoles; Biphenyl Comp | 2021 |
Low-dose candesartan prevents schizophrenia-like behavioral alterations in a neurodevelopmental two-hit model of schizophrenia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2021 |
Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Endothelial Cells; Female; Humans; Hypertension, Pregna | 2018 |
The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs).
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2009 |
Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2009 |
Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2010 |
Developmental effect of antenatal exposure to betamethasone on renal angiotensin II activity in the young adult sheep.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2010 |
Reversible fetal renal failure after maternal treatment with Candesartan: a case report.
Topics: Adult; Amniotic Fluid; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Creatinine; Fema | 2010 |
Acute AT(1)-receptor blockade reverses the hemodynamic and baroreflex impairment in adult sheep exposed to antenatal betamethasone.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Baroreflex; | 2010 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2011 |
Angiotensin receptor blockade in diabetic women of childbearing potential: an acceptable risk?
Topics: Abnormalities, Drug-Induced; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Defective embryogenesis with angiotensin II receptor antagonists in pregnancy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Angiotensin Receptor Antagonists; Antih | 2003 |
Influence of brain angiotensin on thermoregulation and hydromineral balance during pregnancy in rats.
Topics: Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; Body Fluid Compartments; Body Temperature | 2005 |
Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2005 |
Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child, Preschool | 2006 |
Angiotensin-II-receptor inhibitors in pregnancy.
Topics: Abnormalities, Drug-Induced; Acute Kidney Injury; Adult; Antihypertensive Agents; Benzimidazoles; Bi | 2001 |